Reviewing Cytosorbents Corporation (CTSO) and Its Peers
Cytosorbents Corporation (NASDAQ: CTSO) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its rivals? We will compare Cytosorbents Corporation to related businesses based on the strength of its profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.
Insider and Institutional Ownership
6.9% of Cytosorbents Corporation shares are owned by institutional investors. Comparatively, 53.0% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 5.6% of Cytosorbents Corporation shares are owned by company insiders. Comparatively, 17.2% of shares of all “Advanced Medical Equipment & Technology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Cytosorbents Corporation has a beta of -0.52, meaning that its stock price is 152% less volatile than the S&P 500. Comparatively, Cytosorbents Corporation’s rivals have a beta of 0.89, meaning that their average stock price is 11% less volatile than the S&P 500.
This table compares Cytosorbents Corporation and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cytosorbents Corporation Competitors||-327.91%||-35.29%||-12.43%|
This is a breakdown of recent ratings and recommmendations for Cytosorbents Corporation and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cytosorbents Corporation Competitors||253||1813||3255||105||2.59|
Cytosorbents Corporation presently has a consensus target price of $10.45, suggesting a potential upside of 68.55%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 6.82%. Given Cytosorbents Corporation’s stronger consensus rating and higher probable upside, equities analysts plainly believe Cytosorbents Corporation is more favorable than its rivals.
Valuation and Earnings
This table compares Cytosorbents Corporation and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Cytosorbents Corporation||$12.18 million||-$10.41 million||-17.22|
|Cytosorbents Corporation Competitors||$2.02 billion||$430.74 million||-70.34|
Cytosorbents Corporation’s rivals have higher revenue and earnings than Cytosorbents Corporation. Cytosorbents Corporation is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Cytosorbents Corporation rivals beat Cytosorbents Corporation on 8 of the 12 factors compared.
About Cytosorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.
Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.